Quarterly results round-up: Boston swings to loss on goodwill charge, COV, BCR, ROG, ZMH
This article was originally published in Clinica
Executive Summary
Boston Scientific has had a poor second fiscal quarter, seeing revenues shrink 7% and swinging to a net loss. Q2 sales were $1.83bn versus $1.98bn during the same period last year, weighed down by declines in the firm's two biggest units, interventional cardiology (-16% to $549m) and cardiac rhythm management (CRM, -10% to $488m). These businesses have been weak for some time – in Q1, sales fell 5% to $603m and 10% to $501m, respectively (www.clinica.co.uk, 20 April 2012).
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.